 |
|
|
 |
Beta blockers usage low despite insurance
A Duke University Medical Center analysis of a Council for Affordable Quality Healthcare (CAQH) study of more than 15,000 insured patients has shown that during the year after suffering a heart attack, less than half of the patients had been taking beta blockers regularly.
more
|
|
Crucial brain development gene identified
Scientists have identified a gene in mice that is necessary for normal brain development and may contribute to the most common form of primary brain tumors in children. more
|
|
Implanted defibrillators reduce heart failure deaths
An implantable cardiac defibrillator, more commonly referred to as an ICD (ICD) significantly reduces deaths in heart failure patients. The National Heart, Lung, and Blood Institute (NHLBI), one of the National Institutes of Health reports that ICDs save lives and that treatment with the antiarrhythmic drug amiodarone does not reduce deaths in heart failure patients.
more
|
|
|
|
Medicare coverage for ICDs pits costs against benefits for heart failure patients
In a vivid illustration of the tradeoffs that society increasingly faces in this age of costly new medical technology, new research examines the potential impact of Medicare's decision to cover lifesaving implanted devices only for certain heart patients, and not for others.
more
|
|
Information for patients: Facts about heart failure
Heart failure occurs when the heart loses its ability to pump enough blood through the body. Usually, the loss in pumping action is a symptom of an underlying heart problem, such as coronary artery disease. more
|
|
Half of patients studied had some problems adhering to key preventive drugs
It's one of the biggest conundrums in medicine: Why don't patients take the medications their doctors prescribe, even when the drugs could save their lives or prevent their conditions from worsening?
more
|
|
Data shows new drug, rimonabant, helps smokers quit while limiting post cessation weight gain
Researchers at the University of Cincinnati College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared with placebo, markedly reduced post-cessation weight gain at 10 weeks, and was well-tolerated. more
|
|
|
